详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF)

49| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. [2]Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. [4]Department of Pathology, Ningbo Diagnostic Pathology Center, Ningbo, 315021, China. [5]Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China. [6]Department of Rehabilitation, West Kyushu University, Kanzaki-shi, 842-8585, Japan. [7]Department of Urology, Kyung Hee University, Seoul, 446 701, South Korea. [8]Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.

出处：

DOI：

ISSN：

关键词： Pan-cancer RNA 5-methylcytosine ALYREF Immuno-oncological effects

摘要：

The increasing interest in RNA modifications has significantly advanced epigenomic and epitranscriptomic technologies. This study focuses on the immuno-oncological impact of ALYREF in human cancer through a pan-cancer analysis, enhancing understanding of this gene's role in cancer. We observed differential ALYREF expression between tumor and normal samples, correlating strongly with prognosis in various cancers, particularly kidney renal papillary cell carcinoma (KIRP) and liver hepatocellular carcinoma (LIHC). ALYREF showed a negative correlation with most tumor-infiltrating cells in lung squamous cell carcinoma (LUSC) and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), while positive correlations were noted in LIHC, kidney chromophobe (KICH), mesothelioma (MESO), KIRP, pheochromocytoma and paraganglioma (PARD), and glioma (GBMLGG). Additionally, ALYREF expression was closely associated with tumor heterogeneity, stemness indices, and a high mutation rate in TP53 across these cancers. In conclusion, ALYREF may serve as an oncogenic biomarker in numerous cancers, meriting further research attention.© 2024 Ye et al.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2 最新[2023版] 3.1 最新五年平均 2 出版当年[2023版] 0 出版当年五年平均 2 出版前一年[2023版]

第一作者：

第一作者机构： [1]Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Pan-cancer single-cell landscape of drug-metabolizing enzyme genes [2]A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer [3]A novel serum m7G-harboring microRNA signature for cancer detection [4]Selection and Validation of Reference Genes for Pan-Cancer in Platelets Based on RNA-Sequence Data [5]Integrative Analysis Reveals the Landscape of Hypoxia-Inducible Factor (HIF) Family Genes in Pan-Cancer. [6]RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. [7]Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification. [8]Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer [9]A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer [10]A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer